This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Northstar Announces New Product Aimed At Dominating The Multi-billion Dollar Pet Healthcare Industry





HOLBROOK, N.Y., Dec. 6, 2012 /PRNewswire/ -- Northstar Global Business Services, Inc. Symbol (OTCPink: MDIN), today announced plans to release "StemEnrich© For pets", the first stem cell replacement therapy product made specifically for house pets. The new product is a welcomed addition to the company's existing product line which includes the popular products, "Snorenz®", and "Good Night's Sleep®", both of which have been very successful, selling millions of units annually in past years. These products have been on the shelves of large retail chains like Wal-Mart®, Walgreens® and CVS®, and after a two-year break, have already begun shipping to retailers once again with the goal of being distributed through every major retail chain in the US.

We all know pet owners will do and spend just about anything for their pets. Even through a recession, the pet food, food supplement and pet health products industries have grown 6-7% every year reaching over a half trillion dollars annually. Like StemIntense©, another Northstar Product which starts shipping in just a few weeks, StemEnrich© uses special extracts from all natural aquatic algae to increase free flowing adult stem cells in the body of both humans and animals. With vitamins and nutrients specific to domestic dogs and cats added, StemEnrich© can increase the length and quality of life of pets substantially. Independent studies show that these compounds increase muscle and bone strength, decrease the chances of injuries, kill pain, increase eyesight and hearing performance, and give animals more endurance. It's also been shown to increase memory and create an overall happier and clearer mental state according to laboratory tests.

Packaged as a one-a-day treat, StemEnrich will also speed up recovery and healing of injuries, a factor very important since our pets cannot tell us what ails them. "If I knew that giving my dog a small treat every day would make her live longer, and be more comfortable, I would have been making this product years ago. It's especially important for rare breeds who typically have many ailments as a result of genetics," said Nicholas Chieco, Northstar's CEO. "This is basically a one size fits all cure for pets, and I am really proud to think we may help millions of pets live happier lives. It makes you feel really good about what you are doing," he added.

The company plans to release StemEnrich© later in the year through already existing retail channels, most of which have pet sections, making distribution an extension of what the company is already doing, not an entirely new venture. The product will retail for about $9.99 for a 30-day supply and earns the company an estimated $4.25 per unit. The biggest challenge the company faces is manufacturing enough products for the current demand, a problem CEO Nick Chieco is happy to have. Initial projections based on current interest have 2013 projected sales at well over two million units right now, but according to Chieco that number will likely go up, and possibly even surpass the company's other products in sales revenue within three years. Northstar aims to be a major leader in alternative health products, and at their current rate as long as they can line up the manufacturing to fulfill orders, there seems to be no ceiling on the potential earnings for the company's next fiscal year, and no stopping Northstar from supplying alternative health products and supplements to every major retail chain in the world.

About Northstar

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs